agn-151607
abbvie
['dose,study']
superb presentation by at #aha2022 evaluating botulinum toxin for prevention of post-op af. no sig difference in rate of poaf in this dose finding phase 2 study - hypothesis-generating with subgroup analyses suggesting isolated cabg and pts &gt;65 yo who received 125u. 
Director, Electrophysiology and Arrhythmia Services, Cooper University Hospital. Past President Heart Rhythm Society. Opinions are my own.